Abstract: The present application discloses a method of inhibiting the onset of cerebral amyloid angiopathy (CAA) and associated conditions in a subject including administering, to a subject at risk of developing CAA, an antibody-based molecule that binds to GPIIIa49-66 on activated platelets, under conditions effective to inhibit formation of platelet micro-clots, thereby inhibiting the onset of CAA and associated conditions. Also described is a method of reducing cerebral vascular platelet micro-clots in a subject in need thereof and a combination therapeutic that includes an antibody-based molecule that binds to GPIIIa49-66 on activated platelets, and an Alzheimer's disease therapeutic.

Abstract: The present disclosure is directed to a multi-species prion protein or peptide thereof, and vaccine compositions comprising the same that are useful for the vaccination and treatment of mammalian subjects at risk of having or having prion disease. Also disclosed herein are isolated proteins and peptides, polymers, vaccines, animal bait or feed, antibodies, and methods of inhibiting the onset of or treating a prion disease.

Abstract: A fire extinguisher training device comprising a display device for displaying imagery of a fire, a holder for holding the display device, a central member to which the holder is mounted, and an electronic control module mounted to the central member. The device has a trigger mechanism and a trigger sensor for sensing movement of the trigger mechanism, wherein the electronic control module is communicatively connected to the trigger sensor and also to the display device.

Abstract: The present invention is directed to a method of preventing or reducing amyloid deposition in a subject. This method involves selecting a subject with amyloid deposits and stimulating the innate immune system of the selected subject under conditions effective to reduce the amyloid deposits. Also disclosed is a method of preventing or treating cerebral amyloidosis and Alzheimer's Disease in a subject by administering to the selected subject an agent that stimulates the innate immune system. In addition, a composition useful for the stimulation of the innate immune system of a subject exhibiting symptoms associated with amyloid deposition is disclosed.

Abstract: The present invention is directed to a method of preventing or reducing amyloid deposition in a subject. This method involves selecting a subject with amyloid deposits and stimulating the innate immune system of the selected subject under conditions effective to reduce the amyloid deposits. Also disclosed is a method of preventing or treating cerebral amyloidosis and Alzheimer's Disease in a subject by administering to the selected subject an agent that stimulates the innate immune system. In addition, a composition useful for the stimulation of the innate immune system of a subject exhibiting symptoms associated with amyloid deposition is disclosed.

Abstract: The present invention is directed to an anti-prion monoclonal antibody and its use for the treatment of conditions associated with or mediated by proteins or peptides having a toxic oligomeric form. These conditions include, but are not limited to, Alzheimer's disease, frontotemporal dementias, traumatic brain injury, and chronic traumatic encephalopathy.

Abstract: A fire extinguisher training device comprising a display device for displaying imagery of a fire, a holder for holding the display device, a central member to which the holder is mounted, and an electronic control module mounted to the central member. The device has a trigger mechanism and a trigger sensor for sensing movement of the trigger mechanism, wherein the electronic control module is communicatively connected to the trigger sensor and also to the display device.

Abstract: The present invention is directed to a method of preventing or reducing amyloid deposition in a subject. This method involves selecting a subject with amyloid deposits and stimulating the innate immune system of the selected subject under conditions effective to reduce the amyloid deposits. Also disclosed is a method of preventing or treating cerebral amyloidosis and Alzheimer's Disease in a subject by administering to the selected subject an agent that stimulates the innate immune system. In addition, a composition useful for the stimulation of the innate immune system of a subject exhibiting symptoms associated with amyloid deposition is disclosed.

Abstract: The present invention is directed to a method of preventing or reducing amyloid deposition in a subject. This method involves selecting a subject with amyloid deposits and stimulating the innate immune system of the selected subject under conditions effective to reduce the amyloid deposits. Also disclosed is a method of preventing or treating cerebral amyloidosis and Alzheimer's Disease in a subject by administering to the selected subject an agent that stimulates the innate immune system. In addition, a composition useful for the stimulation of the innate immune system of a subject exhibiting symptoms associated with amyloid deposition is disclosed.

Abstract: The present invention is directed to an anti-prion monoclonal antibody and its use for the treatment of conditions associated with or mediated by proteins or peptides having a toxic oligomeric form. These conditions include, but are not limited to, Alzheimer's disease, frontotemporal dementias, traumatic brain injury, and chronic traumatic encephalopathy.

Abstract: The present invention relates to compounds of Formula (I) as defined herein as well as conjugates comprising said compounds and pharmaceutical compositions comprising said compounds or conjugates. Also encompassed are methods for selectively detecting oligomeric proteins or peptides associated with a conformational disorder in a sample, and methods for diagnosing or treating a conformational disorder associated with protein or peptide oligomers in a subject.

Abstract: The invention relates to methods for treating human amyloid disease by administration of modified A? peptide immunogens.

Abstract: Vaccines against prion disease eliciting a humoral immune response when administered mucosally are described. The vaccines comprise a prion protein, a prion protein fragment, or a non-amyloidogenic prion protein homolog and an adjuvant suitable for inducing a humoral immune response after mucosal administration. Suitable adjuvants include cholera toxin subunit B, heat-labile enterotoxin and aluminum hydroxide. Alternatively, the vaccine comprises a vector encoding a prion protein, fragment, or homolog in an attenuated Salmonella host. The vaccines can be used to prevent or treat prion disease in humans and other mammals.

Abstract: The invention relates to methods for treating human amyloid disease by administration of modified A? peptide immunogens.

Abstract: Disclosed herein are methods for treating amyloid disease in humans by clearing amyloid peptides from one or more bodily fluids such as, e.g., blood, of a patient. In particular, the methods are based on the administration of compounds capable of binding to amyloid-beta (A?) or on dialysis of blood or plasma exchange in order to remove A? peptides from the blood circulation, and/or brain or other affected organs.

Abstract: The invention relates to methods for treating human amyloid disease by administration of modified A? peptide immunogens.

Abstract: An in-car communication and entertainment system including an international keyboard having a key (e.g., an ABC key) located on a display/screen (e.g., touch screen) enabling a user to toggle through multiple pages of characters, for example accented or special characters associated with a particular language. The key also includes jewels/indicators representing the amount of pages of characters associated with a particular keyboard wherein each jewel or indicator is lit or highlighted to indicate the specific page. Additionally, another key (e.g., a Globe key) enables the user to change the typing language without changing the system language. In this manner, the international keyboard enables users to interface and communicate with the system in a number of different languages.

Abstract: The invention relates to methods for treating human amyloid disease by administration of modified A? peptide immunogens.

Abstract: Vaccines against prion disease eliciting a humoral immune response when administered mucosally are described. The vaccines comprise a prion protein, a prion protein fragment, or a non-amyloidogenic prion protein homolog and an adjuvant suitable for inducing a humoral immune response after mucosal administration. Suitable adjuvants include cholera toxin subunit B, heat-labile enterotoxin and aluminum hydroxide. Alternatively, the vaccine comprises a vector encoding a prion protein, fragment, or homolog in an attenuated Salmonella host. The vaccines can be used to prevent or treat prion disease in humans and other mammals.

Abstract: The present invention provides a process for producing low fibrillating cellulose fibers by a dry-jet-wet spinning process wherein cellulose is treated with a solvent containing imidazolium ionic salt in a spinneret maintained at a temperature of 100-120° C. and the spun fibers drawn to the coagulation bath containing ionic salt with the draw ratio less than 5, to produce fibers with fibrillating index less than or equal to 3.